Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) FCF Margin (2018 - 2023)

Endonovo Therapeutics has reported FCF Margin over the past 9 years, most recently at 4300.46% for Q3 2023.

  • Quarterly results put FCF Margin at 4300.46% for Q3 2023, down 317034.0% from a year ago — trailing twelve months through Sep 2023 was 246.32% (up 569817.0% YoY), and the annual figure for FY2022 was 501.52%, up 84802.0%.
  • FCF Margin for Q3 2023 was 4300.46% at Endonovo Therapeutics, down from 307.51% in the prior quarter.
  • Over the last five years, FCF Margin for ENDV hit a ceiling of 185.69% in Q4 2022 and a floor of 123827.85% in Q4 2021.
  • Median FCF Margin over the past 5 years was 1096.18% (2019), compared with a mean of 9349.87%.
  • Biggest five-year swings in FCF Margin: plummeted -12215084bps in 2021 and later surged 12364216bps in 2022.
  • Endonovo Therapeutics' FCF Margin stood at 207.74% in 2019, then plummeted by -707bps to 1677.01% in 2020, then plummeted by -7284bps to 123827.85% in 2021, then soared by 100bps to 185.69% in 2022, then crashed by -2216bps to 4300.46% in 2023.
  • The last three reported values for FCF Margin were 4300.46% (Q3 2023), 307.51% (Q2 2023), and 228.47% (Q1 2023) per Business Quant data.